Bmi And Clinical Outcomes In Patients With Metastatic Castration-Resistant Prostate Cancer

BMI and clinical outcomes in patients with metastatic castration-resistant prostate cancer

Metastatic Castration Resistant Prostate Cancer (mCRPC) – Inroads in Improved Outcomes

Grand Rounds in Urology

Treatment options for patients with metastatic castration-resistant prostate cancer

Olaparib + Zytiga for Metastatic Castrate-Resistant Prostate Cancer | Learn About Clinical Trials

Prostate Cancer Research Institute

Cabazitaxel rechallenge in patients with metastatic castration resistant prostate cancer

ESMO Expert Report on combination therapy in advanced prostate cancer @ ASCO GU 2022

European Society for Medical Oncology (ESMO)

Quantitative 68Ga-PSMA-11 PET and Outcomes in Metastatic Castration-resistant Prostate Cancer fol...

Examining Metastatic Castration-Resistant Prostate Cancer Treatment in Black Patients

ZERO Prostate Cancer

How will the results of the SPARTAN study impact US clinical practice in prostate cancer?

Fatigue in men with castration resistant prostate cancer treated with enzalutamide

Dr. Morgan on Olaparib for Metastatic Castration-Resistant Prostate Cancer

ASCO GU24 special: Dr. Kim Chi discusses CONTACT-2 results

European Association of Urology

Should Radium 223 Be Given Earlier to Metastatic Prostate Cancer Patients?

Grand Rounds in Urology

Castration Resistant Prostate Cancer - Developments and Challenges from 2020

Grand Rounds in Urology

PARP inhibitors for the treatment of metastic castration-resistant prostate cancer

Metastatic Castration-Resistant Prostate Cancer by Fellows from UCI

Medical Oncology Association of Southern CA

Testing the Validity of a Prognostic Model for Castration-Resistant Prostate Cancer

Castration Resistant #ProstateCancer | #MarkScholzMD #PCRI

Prostate Cancer Research Institute

Prostate Cancer Debate 2014: Evolving treatment options in castration-resistant prostate cancer

Expert discussion on metastatic castration resistant prostate cancer